Lyra Therapeutics, Inc. (LYRA) Stock Price & Analysis
Lyra Therapeutics, Inc. (LYRA) — price $0.1447 (-3.50%), as of the Oct 5, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Lyra Therapeutics, Inc. · LYRA
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for chronic rhinosinusitis (CRS).
Price as of Oct 5, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.1447 | |
| Change on the day | -3.50% | |
| 52-week range | $0.0004 – $8.75 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Lyra Therapeutics (LYRA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the LYRA film — every key number, told as a short cinematic story
~2 min · open the film
What is Lyra Therapeutics (LYRA), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lyra Therapeutics, Inc. (LYRA) is the company analyzed here. It employs 27 people and is led by Carmichael S. Roberts Jr.. In Q4 FY2025 it reported revenue of $7,000 and net income of -$7M.
What do the latest results show for Lyra Therapeutics (LYRA)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $7,000. Against analyst estimates the company has EPS beat 5 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $7,000 | -$7M | -$0.45 (diluted) |
| Q3 FY2025 | $25,000 | -$6M | -$3.38 (diluted) |
| Q2 FY2025 | $183,000 | -$7M | -$5.51 (diluted) |
| Q1 FY2025 | $183,000 | -$9M | -$0.13 (diluted) |
What are the financial strengths and risks for Lyra Therapeutics (LYRA)?
Short answer
The distress and quality screens read Altman Z -19.16 · Piotroski F 3. Trailing ratios: ROA -80.1% · current ratio 1.71.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -19.16 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Lyra Therapeutics (LYRA)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $700,000 · EPS -7.02 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $700,000
- EPS estimate
- $-7.02
Measured against a quoted price of $0.1447 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 9
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Common Questions About LYRA
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is LYRA a good stock to buy?
Stock Expert AI does not rate LYRA buy, sell or hold. Lyra Therapeutics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LYRA stock price today?
The last price recorded on this page for Lyra Therapeutics, Inc. (LYRA) is $0.1447, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for LYRA?
Evaluate LYRA on fundamentals, analyst consensus, and risk factors. The company's technology delivers medicines directly to the affected tissue for sustained periods with a single administration. Not financial advice.
How frequently does LYRA data refresh on this page?
LYRA's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LYRA's recent stock price performance?
Lyra Therapeutics, Inc. (LYRA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LYRA overvalued or undervalued right now?
Lyra Therapeutics, Inc. (LYRA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LYRA before investing?
Before investing in Lyra Therapeutics, Inc. (LYRA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LYRA to a portfolio?
Key strength of Lyra Therapeutics, Inc. (LYRA): Innovative drug delivery technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (17 figures)
The 17 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.1447 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T14:42:37.000Z. | |
px.change | Change on the day | -3.50% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$0.00525 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 100 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2025 | $7,000 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q4 FY2025 | -$7M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 12 transactions · 0 purchases, 9 sales, 3 other transactions · 4 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.0004 – $8.75 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.employees | Employees | 27 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.ceo | Chief executive | Carmichael S. Roberts Jr. | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-12 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -19.16 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -80.1% · current ratio 1.71 | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $700,000 · EPS -7.02 · 1 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-07-17 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $700,000 | UNRECORDED | Stored analyst estimates — Captured 2026-07-17 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-7.02 | UNRECORDED | Stored analyst estimates — Captured 2026-07-17 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.